BioNTech SE Overview
Pro stress-test →BioNTech is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech is best known for its mRNA technology platform and COVID-19 vaccine. The company is undergoing a strategic transformation from a single-product COVID-focused enterprise toward a diversified oncology platform.
Strategic Profile
Pro stress-test →BioNTech maintained a strong financial position throughout 2025, driven by its revenue-generating COVID-19 vaccine business and strategic partnership with BMS, holding approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025. 2026 is poised to be a catalyst-rich year with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies, with expected 2026 oncology milestones including seven late-stage data readouts and 15 Phase 3 clinical trials.
Competitive Landscape
Pro stress-test →BioNTech is a Germany-based biopharmaceutical company specializing in oncology and infectious disease therapies with a diversified late-stage pipeline spanning immunomodulators, antibody-drug conjugates (ADCs) and mRNA cancer immunotherapies. Key competitors include Moderna (mRNA vaccines/therapies), Pfizer (oncology/vaccines), Genentech/Roche (oncology), and other ADC/immunotherapy developers.
Industry Context
BioNTech SE operates in Biopharmaceuticals - Oncology and Immunotherapy.
Key facts
Founded: 2008 · Headquarters: Mainz, Germany · Revenue: €2.6-2.8B (2025 guidance)